Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — Investor Presentation (June 2024)
15 slides from Argent Biopharma's investor presentation, Jul 1, 2024
Slide 1: Innovative Multidisciplinary Drug Development
For personal use only INNOVATIVE MULTIDISCIPLINARY DRUG DEVELOPMENT Currently focused on the Central nervous system (CNS) June 2024 and Immune Modulation for unmet medical needs Company Presentation
Slide 2: Disclaimer
Disclaimer For personal use only The information contained in this presentation and any accompanying oral presentation use of or reliance on information contained in this document including representations or (“Presentation”) is being supplied to you by Argent BioPharma on behalf of itself and its w
Slide 3: Clinical-Stage, Revenue Generating Biopharmaceutical Company
Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to provide accessible For personal use only medical treatments for unmet medical needs We leverage nanotechnology and multidisciplinary drug development strategies to create multi-target therapies, focusing on central nervous sys
Slide 4: Highly Experienced Argent BioPharma Management Team
Highly Experienced Argent BioPharma Management Team For personal use only Qualified team with versatile industry experience and expertise Roby Zomer Yifat Steuer Igor Bluvstein Amir Polak Sabina Suljaković Yair Tal Managing Director Chief Operating Officer Chief Financial Officer Chief Pharmaceutica
Slide 5: Key Products
For personal use only +Key Products Argent BioPharma 5 Page
Slide 6: CannEpil® Refractory Epilepsy
CannEpil® Refractory For personal use only Epilepsy Revenue Generating Refractory Epilepsy Seizure Control • Approximately 30% of generalized • Accepted by first European country seizure epilepsy patients have and fully covered under the Primary Refractory Epilepsy aka “Drug-Resistant Care Reimburse
Slide 7: CannEpil® Market Potential
CannEpil® Refractory Epilepsy For personal use only Market Potential UK Potential Worldwide Patients with DRE 15M Patients with 150K CannEpil Treatment Estimate, Per Patient £7,0003 DRE Per Annum Key Points • There are 50 million epilepsy sufferers of which 6.21 million in Europe and the UK 1 • Appr
Slide 8: CimetrA® Acute Lung Injury and ARDS
CimetrA® Acute Lung Injury and ARDS Revenue Generating For personal use only Immunomodulation Treatment for Acute Lung Injury (‘ALI’) and Acute Respiratory Distress Syndrome (‘ARDS’) CimetrA® has now been listed under the ArtemiC label as an over-the-counter (OTC) unlicenced drug non-prescription in
Slide 9: CimetrA® Market Potential
CimetrA® Acute Lung Injury and For personal use only ARDS Market Potential Cases of severe illness of influenza worldwide1 3–5M per annum Respiratory deaths1 290–650K per annum Potentially, CimetrA® can be used to treat inflammatory conditions with £100B2 total addressable market Key Points • Sales
Slide 10: CogniCann® Dementia and Alzheimer's
CogniCann® Dementia and Alzheimer’s For personal use only Dementia and Alzheimer’s Designed as a treatment for the Patients’ aggressive behavior symptoms associated with improved by 13%, compared with Dementia and Alzheimer’s the Placebo Group, which improved by 4% The safety and efficacy were asse
Slide 11: IrniCan® Glioblastoma
IrniCan® For personal use only Glioblastoma Glioblastoma The Glioblastoma pre-clinical The study demonstrated that research, conducted IrniCan® was cytotoxic to between 2019-2022 Glioblastoma tumor and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis (or cell d
Slide 12: Research and Development Product Pipeline
Research and Development Product Pipeline For personal use only US FDA & EMA registration Preclinical Phase I Phase IIA Phase IIB Phase III Marketing Authorisation CimetrA© Revenue Generating Acute Lung Injury and ARDS CannEpil® Revenue Generating Refractory Epilepsy CogniCann® Dementia and Alzheime
Slide 13: R&D Centres and Manufacturing Capabilities
For personal use only Argent BioPharma R&D Centres and + Manufacturing Capabilities 13 Page
Slide 14: R&D Centers and Manufacturing Capabilities
R&D Centers and For personal use only Manufacturing Capabilities Integrated research hub • Support the company’s current and future R&D activities • Currently manages and runs clinical trials both in-house* and with third-party CROs • Opportunity for third party revenue generation Fully built GMP ph
Slide 15: Addresses unmet medical needs
For personal use only Addresses unmet medical needs